Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  Draadje OT, bijzaken & geleuter in de marge!

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

Draadje OT, bijzaken & geleuter in de marge!

1.189 Posts
Pagina: «« 1 2 3 4 5 6 ... 60 »» | Laatste | Omlaag ↓
  1. [verwijderd] 30 maart 2006 13:07
    Market Talk: Geen belangenconflict voor Galapagos30 mrt 2006, 12:14 uur
    AMSTERDAM (Dow Jones)--De samenwerking van Galapagos met Arthrogen voor targets, ofwel eiwitten die de basis vormen voor de ontwikkeling van nieuwe geneesmiddelen tegen reuma, levert geen belangenconflict op, stelt Kempen & Co. De bank zegt dat beide bedrijven weliswaar onderzoek doen naar een potentieel geneesmiddel voor rheumatoide arthritis, maar dat Galapagos actief is op het gebied van kleine moleculen en Arthrogen met gentherapie. "Simpel gesteld zijn dit verschillende gebieden die vragen om verschillende targets", aldus Kempen.

    De zakenbank heeft het aandeel op 'buy', bij een koersdoel van 12 euro.

    Het aandeel Galapagos noteert donderdag rond 12.13 uur 3,5% hoger op 9,85 euro.

    Dow Jones Nieuwsdienst; +31-20-5890270;

  2. [verwijderd] 30 maart 2006 16:15

    AVI BioPharma Reports Successful Inhibition of Multiple Subtypes of Influenza A Using NEUGENE Antisense Therapeutic
    Business Wire - March 30, 2006 09:00
    Preclinical Results by Four Independent Laboratories Summarized and Presented at Keystone Symposia: Advances in Influenza Research

    PORTLAND, Ore., Mar 30, 2006 (BUSINESS WIRE) -- AVI BioPharma, Inc. (Nasdaq:AVII), today announced the presentation of research results titled "Inhibition of Multiple Subtypes of Influenza A Virus in Cell Culture with Morpholino Oligomers" at the Keystone Symposia conference "Advances in Influenza Research: From Birds to Bench to Bedside." The symposium will be held March 28 to April 2, 2006, in Steamboat Springs, Colo.

    "Our presentation summarizes the results from AVI's collaborations with four independent research laboratories from around the world," said Patrick L. Iversen, Ph.D., senior vice president of research and development at AVI. "The key finding here is that our NEUGENE(R) therapeutics continue to show efficacy against all strains of influenza A, including H5N1, the avian influenza strain that is currently causing global concern as a potential pandemic pathogen."

    The poster presentation includes results generated by researchers at the Massachusetts Institute of Technology, Cambridge, Mass.; Mahidol University, Bangkok, Thailand; the Public Health Agency of Canada, Winnipeg, Manitoba; and Oregon State University, Corvallis, Ore.

    The summary results show that AVI's NEUGENE agents targeting a highly conserved region in the genetic start-site of influenza A viruses were highly effective in inhibiting replication of multiple influenza A subtypes, including H1N1, H3N2, H3N8, H5N1 and H7N7. This suggests that a single NEUGENE agent could be developed to inhibit replication of multiple strains of Influenza A virus.

    Based on these findings, as well as the results generated by additional studies in other viruses, AVI plans to file an IND application with the FDA later this year for the treatment of influenza A virus using NEUGENE antisense drugs.

    About Influenza A Viruses

    Influenza, or flu, is a contagious respiratory illness caused by influenza viruses. On average 5 percent to 20 percent of the U.S. population are infected with the flu each year, resulting in 36,000 deaths. Influenza A virus is an enveloped negative-strand RNA virus, with eight genome segments that code for 10 proteins. Influenza strains are subtyped according to the antigenic and genetic nature of their surface glycoproteins: hemagglutinin (HA or H) and neuraminidase (NA or N). Fifteen H and nine N subtypes have been identified, with three associated with widespread human disease (H1N1, H2N2 and H3N2). In addition, several subtypes of avian influenza virus -- H5N1, H7N7 and H9N2 -- can infect and cause disease in humans.

    The current influenza pandemic in birds throughout Asia and in Eastern Europe is caused by the H5N1 subtype. It is thought that co-infection of man or certain animals (such as pigs) with both H1N1 and H5N1 can lead to a reassortment or recombination of viral particles, resulting in the emergence of virus with dangerous public health properties, namely new antigens to which the human population does not have immunity and which have the ability to spread from person to person. It is believed that emergence of avian flu by this general mechanism may have led to the worldwide pandemics of 1918, 1957 and 1968.

    Dirk


  3. [verwijderd] 30 maart 2006 16:17
    Genentech and Biogen Idec Submit Supplemental Biologics License Application for First-Line Use of Rituxan in Low-Grade or Follicular CD20-Positive B-Cell Non-Hodgkin’s Lymphoma


    South San Francisco, Calif. and Cambridge, Mass. -- 30 maart 2006 -- Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) announced today that the companies submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for the use of Rituxan® (Rituximab) as first-line treatment of previously-untreated patients with low-grade or follicular, CD20-positive, B-cell nonHodgkin's lymphoma in combination with CVP (cyclophosphamide, vincristine and prednisone) or CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy or following CVP chemotherapy in those patients who achieved a response of stable disease or better.
    www.gene.com/gene/news/press-releases...
  5. [verwijderd] 30 maart 2006 21:28
    bijvoorbeeld zo:

    504 Teletekst do 30 mrt
    ***************************************
    *************************************
    Technofondsen Amsterdam in de lift
    ***************************************
    ` De beleggers in Amsterdam lieten zich
    vandaag leiden door de hogere koersen
    van de beurzen in de VS en Japan.Vooral
    de technologie-aandelen stegen,na het
    hogere slot van de Nasdaq in New York.

    In Amsterdam betekende dat winst voor
    onder meer Getronics,ASML en ASMI.Een
    grootaandeelhouder van dat ASMI heeft
    geëist dat de aandeelhouders binnenkort
    een opsplitsing van het hightechbedrijf
    in stemming brengen.

    De AEX-index besloot de dag op 472,58
    punten,een winst van 0,77 procent.Voor
    de MidKap was er ook 0,7% winst.Ook op
    de andere beurzen in Europa besloten de
    graadmeters de dag met flinke winsten.

    ===========================================

    Dus eerst in tekstmodus (T) zetten en dan copy/paste.

    Je kan natuurlijk ook een foto nemen van je TV of PC en dan als fotobestandje toevoegen ...

    WB

  6. gogogoo 30 maart 2006 21:30
    quote:

    voda schreef:

    Ik heb deze vraag al eerder gesteld, maar helaas geen antwoord gekregen!

    Hoe kan ik een bericht van de nosteletekst transporteren naar een forum?

    Iemand deze keer?

    Voda

    teletekst.nos.nl/
    Klik dan op de T-knop een beetje naar rechts boven.
    Dan CTRL-C en CTRL-V.

    Bedoel je dat?

    Edit: hè, net te laat
  7. forum rang 4 Opstapelen 30 maart 2006 21:32
    quote:

    voda schreef:

    Ik heb deze vraag al eerder gesteld, maar helaas geen antwoord gekregen!

    Hoe kan ik een bericht van de nosteletekst transporteren naar een forum?

    Iemand deze keer?

    Voda

    Voda ik geloof dat ik je van dienst kan zijn.
    Je moet eerst de betreffende pagina in text mode zetten, dat kan je direct boven de pagina aanklikken. Daarna de hele boel selecteren. Rechtermuisknop en dan kopieren, naar het Crucell forum en plakken.
    Probeer maar eens,
    Erik
  8. gogogoo 30 maart 2006 21:32
    quote:

    WarrumBuffet schreef:

    bijvoorbeeld zo:

    504 Teletekst do 30 mrt
    ***************************************
    *************************************
    Technofondsen Amsterdam in de lift
    ***************************************
    ` De beleggers in Amsterdam lieten zich
    vandaag leiden door de hogere koersen
    van de beurzen in de VS en Japan.Vooral
    de technologie-aandelen stegen,na het
    hogere slot van de Nasdaq in New York.

    In Amsterdam betekende dat winst voor
    onder meer Getronics,ASML en ASMI.Een
    grootaandeelhouder van dat ASMI heeft
    geëist dat de aandeelhouders binnenkort
    een opsplitsing van het hightechbedrijf
    in stemming brengen.

    De AEX-index besloot de dag op 472,58
    punten,een winst van 0,77 procent.Voor
    de MidKap was er ook 0,7% winst.Ook op
    de andere beurzen in Europa besloten de
    graadmeters de dag met flinke winsten.

    ===========================================

    Dus eerst in tekstmodus (T) zetten en dan copy/paste.

    Je kan natuurlijk ook een foto nemen van je TV of PC en dan als fotobestandje toevoegen ...

    WB

    En die foto laten afdrukken, inscannen en met OCR laten omzetten naar platte tekst en dan copy paste.
  11. [verwijderd] 31 maart 2006 08:21
    Elke ochtend kijk ik met een schuin oog naar het rechtsboven kolommetje op AEX en bijna elke ochtend slaat die IEX computer al op hol.
    Zo ook deze morgen waar om 8.20 uur zowel DSM (+1.88)als Philips(+1.56) al weer ruim gestegen zijn.
    Toch knap in een land waar er geen voorbeurshandel bestaat.

    Giraf
  13. [verwijderd] 31 maart 2006 08:59
    Inkoop eigen aandelen voor lopende management- en personeelsoptie-programma’s

    Heerlen,NL,31-mrt-2006


    Koninklijke DSM N.V. maakt bekend dat zij vanaf 31 maart tot 7 april 2006, een maximum aantal van 1.850.000 eigen aandelen wil inkopen om op de gebruikelijke wijze te voldoen aan de door DSM gestelde afdekkingsverplichtingen van de lopende management- en personeelsoptie-programma’s. Het maximale bedrag dat is gemoeid met de inkoop bedraagt EUR 82 miljoen.
    www.dsm.com/nl_NL/html/media/press_re...
  14. [verwijderd] 31 maart 2006 10:16
    Arabieren in Galapagos
    Het Nederlands-Belgische biotechbedrijf Galapagos gaat samen met Arthrogen onderzoek doen naar medicijnen voor reumatoïde artritis. De deal heeft een link met het miljarden dollars kostende zorgcomplex dat in Dubai uit de grond gestampt wordt. Arthrogen komt namelijk voort uit een samenwerkingsverband waarin Dubai Bone & Joint Center een voorname rol speelt. (Tel, p.25)
  15. [verwijderd] 31 maart 2006 11:43
    quote:

    h.vdbilt schreef:

    Arabieren in Galapagos
    Het Nederlands-Belgische biotechbedrijf Galapagos gaat samen met Arthrogen onderzoek doen naar medicijnen voor reumatoïde artritis. De deal heeft een link met het miljarden dollars kostende zorgcomplex dat in Dubai uit de grond gestampt wordt. Arthrogen komt namelijk voort uit een samenwerkingsverband waarin Dubai Bone & Joint Center een voorname rol speelt. (Tel, p.25)
    En het aandeel breekt door de tien euro!!!
  16. [verwijderd] 31 maart 2006 15:25
    March 31, 2006 08:10 AM ET
    Serono to raise capital for possible acquistions

    Serono surprised investors on Friday with plans to raise about SFr7.3bn ($5.6 billion) for potential acquisitions through issuing new shares after failing to attract a buyer for the Swiss biotechnology company.

    Shares, which fell as much as 9 per cent, were 6 per cent lower by mid-morning at SFr909.5.

    Serono hired Goldman Sachs last November to find "strategic options" for the Bertarelli family's controlling 62 per cent stake. A number of large pharmaceutical groups - including GlaxoSmithKline, Novartis and Pfizer had been tipped as buyers. However, the company's attractiveness has been in doubt as its top-selling multiple sclerosis drug Rebif faces the prospect of growing competition, coupled with Serono's weak pipeline of new drugs to replace possible lost sales.

    On Friday, Serono said it would seek shareholder approval to provide it with the financial capacity to pursue possibilities that include an acquisition. "The strategic review announced in November 2005 is on-going and could result in a sale of, merger of, or one or more acquisitions by, the company," it said in a statement.

    The company plans to issue up to 7.6m new bearer shares that are worth about SFr 7.3bn based on Serono's closing share price on Thursday.

    The capital increase would be worth around 7.3 billion Swiss francs ($5.6bn), based on Thursday's closing price. Serono, which has a market capitalisation of $10.4bn, said that the capital increase could be executed all at once or in instalments.
    news.moneycentral.msn.com/provider/pr...
  19. [verwijderd] 31 maart 2006 21:14
    Mooi IMO.
    *********
    31 March 2006
    New device could cut chemotherapy deaths

    A new method of delivering chemotherapy to cancer patients without incurring side effects such as hair loss and vomiting is being developed.

    The method, produced at the University of Bath, involves using tiny fibres and beads soaked in the chemotherapy drug which are then implanted into the cancerous area in the patient’s body.

    These fibres are bio-degradable and compatible with body tissue, which means they would not be rejected by the patient’s body. They gradually turn from solid to liquid, releasing a regular flow of the chemotherapy chemical into the cancer site, and a much lower dose to the rest of the body.

    This is a more localised way of killing cancer cells than the current method of injecting the chemical into a cancer sufferer’s vein so that it is carried around the body.

    As well as reducing the side-effects, the new drug delivery vehicle, known as Fibrasorb, could also cut the numbers of patients who die from the effects of chemotherapy because they need such high doses to tackle their cancer.

    The method, developed by Dr Semali Perera, of the University's Department of Chemical Engineering, over the past few years, has successfully gone through preliminary laboratory trials. The first clinical trials on volunteer patients with ovarian cancer in Avon, Somerset and Wiltshire could begin in the next few years and, if successful, the technology could be put into general use.

    The research team at Bath is collaborating closely with the Avon, Somerset and Wiltshire Cancer Centre and the oncology team at the Royal United Hospital for the design and development of these drug delivery vehicles. This team includes Dr Ed Gilby, one of the most experienced consultant oncologists, surgeons Mr Nicholas Johnson and Mr Kenneth Jaaback, clinical trials experts and specialist nurses such as Tracie Miles.

    “Side effects from chemotherapy can be very unpleasant and sometimes fatal,” said Dr Perera.

    “The new fibres and beads could cut out some side-effects entirely, including nausea and vomiting, and could reduce the number of people who die each year.

    “Although the first study will be on patients with ovarian cancer, soon we hope that other cancer sufferers with solid tumours will benefit.

    “Give that around one in eight people worldwide die of cancer, this could be a vitally important step in the treatment of this disease.

    “We have now assembled an extremely experienced team to develop the Fibrasorb technology."

    The Fibrasorb technology is a flexible fully resorbable device that can be formulated as a bead, a fibre or mesh, or as a tube put into the body which leads outside the body and through which drugs can be fed.

    For the pre-clinical studies, funded by the Department of Health, Dr Perera will be working closely with Dr Vasanta Subramanian, a lecturer in the University's Department of Biology & Biochemistry. Dr Subramanian is a cell and molecular biologist with extensive research experience in gastrointestinal cancers and stem cells in the gastrointestinal tract.

    Dr Perera has also been working with the University's Department of Pharmacy & Pharmacology to make the fibres more sterile so they cannot be attacked by harmful bacteria.

    Dr Perera said that other researchers had worked on using tiny beads as a way of delivering drugs locally, but the new system showed greater promise because it could achieve better control when delivering the drug.

    A patent application has been filed on the drug delivery system, and drug companies across the world are expected to express great interest in the new technology. Dr Perera has been working closely with David Coleman and Jennie Solbé from the University’s Research Innovation Services department, to develop this technology. Her students, who have made a valuable contribution to the project, include Chin Chi Tai, Christopher Campbell and Ian Lee.
    www.bath.ac.uk/news/articles/releases...
  20. [verwijderd] 31 maart 2006 21:18
    March 30, 2006
    New Human Retrovirus Originated in Mice

    Howard Hughes Medical Institute researchers and their colleagues have discovered a new retrovirus in humans that is closely related to a cancer-causing virus found in mice. Their findings describe the first documented cases of human infection with a retrovirus that is native to rodents.

    The researchers discovered the virus in patients with a rare type of prostate cancer. The patients in the study have a genetic mutation that compromised some of their natural defenses against viral infection. Thus, the researchers said their discovery raises the possibility that increased susceptibility to viral infection may play a role in development of some cancers. However, they emphasized that their findings by no means implicate the virus, dubbed XMRV, in causing prostate cancer. The virus may well have flourished as a result of the failure of the defense mechanism; and other factors such as chronic inflammation may play a more direct role in the cancer.

    “This finding was a big surprise because most of these endogenous viral genomes have undergone such mutation and deletion that they are incapable of giving rise to viruses any more.”
    Don Ganem
    Lees verder via www.hhmi.org/news/derisi20060331.html
1.189 Posts
Pagina: «« 1 2 3 4 5 6 ... 60 »» | Laatste |Omhoog ↑

Direct naar Forum

Indices

AEX 903,61 0,00%
EUR/USD 1,0853 +0,05%
FTSE 100 8.275,38 +0,54%
Germany40^ 18.585,90 +0,48%
Gold spot 2.321,22 -0,27%
NY-Nasdaq Composite 16.735,02 -0,01%

Stijgers

AALBER...
0,00%
ABN AM...
0,00%
Accsys
0,00%
ACOMO
0,00%
ADYEN NV
0,00%

Dalers

AALBER...
0,00%
ABN AM...
0,00%
Accsys
0,00%
ACOMO
0,00%
ADYEN NV
0,00%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!